

# Financial Tear Sheet

## Corporate Profile

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Fibrocell's most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of vocal fold scarring resulting in chronic or severe dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin and joint diseases using genetically-modified autologous fibroblasts. Fibrocell is in preclinical development of FCX-007, its orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in preclinical development of FCX-013, its gene-therapy product candidate, for the treatment of linear scleroderma. In addition, Fibrocell and Intrexon will be commencing preclinical development of a gene therapy for the treatment of chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions

## Stock Information

### FCSC (Common Stock)

<b>Exchange</b>	NASDAQ CM (US Dollar)
<b>Price</b>	<b>\$2.05</b>
<b>Change (%)</b>	<b>▲ 0.03 (1.49%)</b>
<b>Volume</b>	74,033
<b>52 Week Low</b>	\$1.45
<b>Market Cap</b>	\$19,095,713
<b>Rolling EPS</b>	-0.04
<b>PE Ratio</b>	N/A
<b>Shares Outstanding</b>	9,314,982

Data as of 01/17/19 12:15 p.m. ET



## Recent Headlines & Events

01/16/19 - 8:00 a.m.  
Fibrocell to Present at Phacilitate Leaders World 2019

12/11/18 - 8:01 a.m.  
Fibrocell Receives \$900,000 Investment from EB Research Partnership and Epidermolysis Bullosa

Date	Title
01/23/19 2:05 p.m. ET	<b>Phacilitate Leaders World 2019</b> <b>Location</b> Miami, FL

Medical Research Foundation

11/13/18 - 8:00 a.m.

Fibrocell Reports Third Quarter 2018 Financial Results and Recent Highlights

**SEC Filings**

Filing Date	Form
01/08/19	8-K
01/04/19	SC 13G/A
12/20/18	D
12/11/18	8-K

**Corporate Governance**

Douglas J. Swirsky	Chairman of the Board
Julian P. Kirk	Director
Marc B. Mazur	Director
John Maslowski	Director
Kelvin D. Moore	Director
Marcus E. Smith	Director
Christine St.Clare	Director

**Ownership Summary**

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	33	9.01	42.5	3,955,504
Mutual Fund	11	.24	1.6	152,770
Director and Officer	1	.01	0.0	3,164

\*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
Third Security, LLC	1,653,486	17.8	0	09/30/18
Anson Funds Management LP.	679,408	7.3	679,408	05/29/18
Sabby Management, LLC	464,818	5.0	-214,590	12/31/18
Renaissance Technologies LLC	367,941	4.0	205,660	09/30/18
Intracoastal Capital, L.L.C.	335,466	3.6	335,466	07/11/18
MSD Partners, L.P.	138,432	1.5	-160	09/30/18
The Vanguard Group, Inc.	125,394	1.4	1,403	09/30/18
Creative Planning, Inc.	45,677	0.5	8,475	09/30/18
Virtu Americas LLC	20,906	0.2	-3,551	12/31/18
PanAgora Asset Management Inc.	16,698	0.2	1,109	09/30/18

Data provided by Nasdaq. Minimum 15 minutes delayed.